Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small cell lung cancer.
|Poll|November 30, 2012
A 74-Year-Old Caucasian Man Presents With Asymptomatic Navel “Lump”
Author(s)Ted Rosen, MD
A 74-year-old, previously healthy, nonsmoking Caucasian male presented with a 4-month history of an asymptomatic “lump” in the navel. Biopsy of the umbilical nodule revealed adenocarcinoma. The most likely primary site of this patient’s malignancy is . . . ?
Advertisement
A 74-year-old, previously healthy, nonsmoking Caucasian male presented with a 4-month history of an asymptomatic “lump” in the navel. Review of systems revealed an involuntary 17-pound weight loss during the previous 6 months and intermittent localized abdominal pain of mild to moderate severity. Recent routine laboratory values and chest radiograph were within normal limits. A carcinoembryonic antigen (CEA) level was 55 ng/mL (severely elevated). A fecal occult blood test was positive. Physical examination disclosed a firm 3.5 cm × 3 cm violaceous nodule occupying the central umbilicus, surrounded by a narrow rim of similarly colored, indurated periumbilical skin. Biopsy of the umbilical nodule revealed adenocarcinoma.
The most likely primary site of this patient’s malignancy is . . . ?
Advertisement
Related to this article
Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.
The FDA granted priority review to perioperative durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive disease, based on phase 3 VOLGA data.
Longer follow-up is needed for the phase 3 MIDAS trial to determine the impact of MRD conversion on progression-free survival and overall survival.
The FDA cleared TriSalus’s TriNav Advance device, which extends the SmartValve-based drug delivery technology to improve tumor penetration during liver embolization.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
2
Acting on a HER2 Result and Navigating Access to Therapy
3
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
4
FDA Clears TriNav Advance for Expanded Liver Embolization Access
5